<DOC>
	<DOCNO>NCT00238329</DOCNO>
	<brief_summary>RATIONALE : PEG-interferon alfa-2b may interfere growth tumor cell . Biological therapy , thalidomide , may stimulate immune system different way stop tumor cell grow . PEG-interferon alfa-2b thalidomide may also stop growth melanoma block blood flow tumor . Giving PEG-interferon alfa-2b together thalidomide may effective treatment melanoma . PURPOSE : This phase II trial study well give PEG-interferon alfa-2b together thalidomide work treat patient recurrent metastatic melanoma .</brief_summary>
	<brief_title>PEG-Interferon Alfa-2b Thalidomide Treating Patients With Recurrent Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient recurrent metastatic malignant melanoma treat PEG-interferon alfa-2b thalidomide . - Determine quantitative qualitative toxic effect regimen patient . - Determine progression-free overall survival patient treat regimen . OUTLINE : Patients receive PEG-interferon alfa-2b subcutaneously weekly oral thalidomide daily . Treatment continue least 2 week 8 month absence disease progression unacceptable toxicity . Patients achieve complete response ( CR ) receive PEG-interferon alfa-2b thalidomide 2 month beyond documentation CR . PROJECTED ACCRUAL : A total 18-32 patient accrue study within 14-38 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant melanoma , include follow : Cutaneous melanoma Ocular melanoma Mucosal melanoma Unidentified primary tumor Recurrent metastatic disease Bidimensionally measurable evaluable disease Brain metastases allow provided disease stable ≥ 6 week prior radiotherapy PATIENT CHARACTERISTICS : Age 18 Performance status SWOG 02 Life expectancy At least 12 week Hematopoietic Absolute granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ 2 time upper limit normal ( ULN ) SGOT ≤ 2 time ULN Renal Creatinine ≤ 2 mg/dL Cardiovascular None follow condition within past 3 month : Congestive heart failure Second thirddegree heart block Myocardial infarction Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublemethod contraception ( 1 highly effective 1 additional method ) ≥ 4 week , , ≥ 4 week completion study treatment No malignancy within past 2 year except adequately treated skin cancer carcinoma situ cervix No concurrent blood , sperm , ova donation PRIOR CONCURRENT THERAPY : Biologic therapy Prior biologic therapy ( e.g. , interferon ) allow Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy See Disease Characteristics At least 28 day since prior radiotherapy Surgery At least 28 day since prior surgery Other No 2 prior systemic treatment regimens metastatic malignant melanoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>ciliary body choroid melanoma , medium/large size</keyword>
	<keyword>extraocular extension melanoma</keyword>
	<keyword>iris melanoma</keyword>
	<keyword>recurrent intraocular melanoma</keyword>
</DOC>